WordPress database error: [Disk full (/tmp/#sql-temptable-4a8-4d31b5-2157.MAI); waiting for someone to free some space... (errno: 28 "No space left on device")]SHOW FULL COLUMNS FROM `RTdvC2C_options`
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).
The WFH Shared Decision Making (SDM) Workbook is for people with hemophilia A or B and their healthcare team. It
The World Federation of Hemophilia (WFH) Shared decision-making (SDM) tool helps clinicians and people with hemophilia work together to make
The WFH Shared Decision Making (SDM) Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between
This fact sheet contains commonly asked questions and more information on gene therapy for hemophilia B. Learn more about different
This video gives a quick introduction to hemostatic rebalancing therapy. Learn more about different treatment options for hemophilia with the
This video gives a quick introduction to gene therapy for hemophilia. Learn more about different treatment options for hemophilia with
